Belumosudil Dosage
Medically reviewed by Drugs.com. Last updated on Jun 11, 2025.
Applies to the following strengths: 200 mg
Usual Adult Dose for:
Usual Pediatric Dose for:
Additional dosage information:
Usual Adult Dose for Graft Versus Host Disease
200 mg orally once a day
Duration of therapy: Until progression of chronic Graft Versus Host Disease (GVHD) that requires new systemic therapy
Use: For the treatment of patients with GVHD after failure of at least two prior lines of systemic therapy
Usual Pediatric Dose for Graft Versus Host Disease
- 12 to less than 18 years:
- Duration of therapy: Until progression of chronic Graft Versus Host Disease (GVHD) that requires new systemic therapy
Use: For the treatment of patients with GVHD after failure of at least two prior lines of systemic therapy
Renal Dose Adjustments
Data not available
Comments:
- For patients with preexisting severe renal impairment, consider the risks and potential benefits before initiating therapy with this drug.
Liver Dose Adjustments
- Mild Liver Dysfunction (Child-Pugh Class A): No dose adjustment recommended
- Moderate or Severe Liver Dysfunction (Child-Pugh Class B or C) without liver GVHD: Avoid use
HEPATOTOXICITY:
- Grade 3 AST/ALT (5 times to 20 times upper limit of normal [ULN]) or Grade 2 bilirubin (1.5 to 3 x ULN): Withhold therapy until recovery of bilirubin, AST, and ALT to Grade 0 or 1 then resume therapy at the recommended dose.
- Grade 4 AST/ALT (more than 20 x ULN) or Grade 3 or greater bilirubin (more than 3 x ULN): Permanently discontinue therapy.
Dose Adjustments
OTHER ADVERSE REACTIONS:
- Grade 3: Withhold therapy until recovery to grade 0 or 1, then resume therapy at the recommended dose.
- Grade 4: Permanently discontinue therapy.
ADJUSTMENTS DUE TO DRUG INTERACTIONS
- Coadministration with strong CYP450 3A inducers: Increase dose to 200 mg orally twice a day
- Coadministration with proton pump inhibitors: Increase dose to 200 mg orally twice a day
Precautions
CONTRAINDICATIONS: None
Safety and efficacy have not been established in patients younger than 12 years.
Consult WARNINGS section for additional precautions.
Dialysis
Data not available
Other Comments
Administration advice:
- Swallow tablets whole. Do not cut, crush, or chew tablets.
- This drug should be taken with a meal at approximately the same time daily.
- If a dose is missed, the patient should take this drug as soon as possible on the same day; do not take extra doses to make up the missed dose.
- Dispense this drug to the patient in the original container.
Storage requirements:
- Store at 20C to 25C (68F to 77F); excursions permitted to 15C to 30C (59F to 86F).
- Store in the original container to protect from moisture.
Monitoring:
- Hepatic: Bilirubin, AST, and ALT (at least monthly)
General:
- Health care professionals are encouraged to report any suspected adverse reactions at www.fda.gov/medwatch.
Patient advice:
- Read the US FDA-approved patient labeling (Patient Information).
- Inform your healthcare provider of all your medications, including herbal products, over-the-counter drugs, and vitamins.
- Women of reproductive potential should:
- Inform their health care provider if they plan to become pregnant and be advised of the potential risk to the fetus
- Contact their health care provider if they become pregnant or suspect a pregnancy
- Use effective contraception during treatment and for 1 week after the last dose
- Breastfeeding is not recommended during treatment and for at least 1 week after the last dose.
- Males and females of reproductive potential should be informed that this drug may impair fertility.
- Males with female partners of reproductive potential should use effective contraception during treatment and for at least 1 week after the last dose.
More about belumosudil
- Check interactions
- Compare alternatives
- Side effects
- During pregnancy
- Drug class: selective immunosuppressants
- Breastfeeding
- En español
Patient resources
Other brands
Professional resources
Other brands
Related treatment guides
See also:
Further information
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.